New Study: Celiac Disease Drug Reduces Intestinal Damage

Early results from a study on a new drug to treat celiac disease, ZED1227, found that those who took varying doses of ZED1227 had a greater reduction in intestinal damage compared to study participants who were given a placebo. All participated in a gluten challenge, ie purposely eating gluten. ZED1227 is the first non-dietary treatment that has preliminarily shown the capacity to prevent mucosal damage in persons with celiac disease, and all the patients who received ZED1227 reported an increase in quality of life. On developing a celiac disease treatment, the study authors explained that the gluten-free diet is, for some, an inadequate treatment. They note that “only 50 percent of patients have mucosal recovery” and often do not have negative results in blood tests for celiac disease even one year after diagnosis. “There is an unmet medical need for an effective treatment adjunct to a strict gluten-free diet,” they write. The group plans to launch a larger study in a real-world setting to further study the drug. Read more about the study: https://hubs.li/H0RtT1R0Thank you to Beyond Celiac's Amy Ratner for summarizing the study findings!I would love to hear from you! Leave your messages for Andrea at [email protected] and check out www.baltimoreglutenfree.comInstagramFacebookGluten Free College 101Website: www.glutenfreecollege.comFacebook: http://www.Facebook.com/Glutenfreecollege Hosted on Acast. See acast.com/privacy for more information.